Thomas Barnes from Intellia Therapeutics gave a talk to Corn Lab

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

November 29, 2024

BE AWARE: GENOME EDITING WITH DNA-PKCS INHIBITOR AZD7648 INDUCES SIGNIFICANT GENOMIC ALTERATIONS – PUBLISHED IN NATURE BIOTECHNOLOGY

Genome editing creates double-strand breaks (DSBs) that can be repaired through either non-homologous end joining (NHEJ), microhomology-mediated end...

November 25, 2024

Welcome Tijana!

Tijana Nikic received her MSc in Human Biology from LMU Munich, completing her thesis in 2022 with Prof. Dr. Stefan Stricker on understanding astrocyte cell...

November 21, 2024

Congratulations to Lilly!

We are thrilled to announce that Lilly has successfully defended her PhD! Her research focused on monitoring genome editing by visualizing DNA repair. She...

News Archive

Tweets